Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007112 (prostatic adenocarcinoma)
 2,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-seven patients with metastatic adenocarcinoma of the prostate were treated with the new luteinizing hormone-releasing hormone analog, Zoladex (ICI 118,630) for up to ninety-eight weeks. Initially, treatment was randomized between Zoladex 250 micrograms and 500 micrograms self-injected subcutaneously every day for a minimum period of twelve weeks following which a sustained-release, once-monthly depot formulation of Zoladex 3.6 mg s.c. was used. Acute rises in serum gonadotropins and testosterone during the first two days were followed by declines in hormone levels over the following three weeks. Median time to castration with 500 micrograms/day was twenty-two days compared with forty-three days with 250 micrograms/day (p = 0.06). No significant endocrinologic changes occurred during the transfer to the depot, and serum testosterone remained 95 per cent suppressed throughout the duration of the study. After three months the median daily serum Zoladex concentrations ranged between 0.47 and 0.53 ng/ml and were not significantly different among the three dosage forms. No specific correlation among serum Zoladex concentrations, endocrinologic parameters, and tumor response rates were found. Hot flashes initially, and decreased libido were the only common complaints. Zoladex was well tolerated, and no side effects required dose-modification or removal from the study. Tumor response rates up to one year appeared to be comparable to the conventional endocrine therapies. This analog in monthly depot formulation is recommended for further clinical evaluation.
 ...
PMID:Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma. 294 17

Relapsing polychondritis is a chronic rheumatologic disorder of unknown etiology. Cutaneous manifestations occur in nearly half of the patients and often precede cartilaginous involvement. We present the case of a man with a history of prostatic adenocarcinoma who underwent monthly injections of goserelin (Zoladex), an LH-RH analogue. Five months after the beginning of the treatment, he presented cutaneous manifestations, which then recurred monthly, after each goserelin injection. After goserelin interruption and replacement with another treatment (cyproterone acetate), the patient was asymptomatic for 2 months. A cutaneous relapse then occurred followed by a typical cartilaginous involvement. In our observation, goserelin seems to have triggered the cutaneous manifestations of relapsing polychondritis. An hormonal precipitating factor in relapsing polychondritis has already been suggested by reports of patients whose disease worsened under chorionic gonadotropin treatment or during pregnancy.
 ...
PMID:Cutaneous manifestations of relapsing polychondritis in a patient receiving goserelin for carcinoma of the prostate. 952 65

A 53-year-old man presented to our department with acute urinary retention and an approximate 8-year history of frequent urination, dysuria, poor urinary stream and nocturia. His prostate-specific antigen (PSA) values were normal (<4 ng/ml) upon repeated testing. The patient was diagnosed with benign prostatic hyperplasia, although there was no significant improvement in his symptoms after treatment with oral finasteride and doxazosin. He then underwent transurethral resection of the prostate in February 2013, and histopathological examination showed adenocarcinoma of the prostate. His treatment regimen included daily oral bicalutamide and subcutaneous injection of Zoladex once per month. Three months later, radical prostatectomy was performed, and a prostate histopathological examination indicated primary urothelial carcinoma with glandular differentiation. His PSA values were normal (<4 ng/ml) before and after the radical prostatectomy. After the second operation, the patient received chemotherapy with gemcitabine and cisplatin. Two months later, magnetic resonance imaging (MRI) indicated local tumor recurrence. The patient was treated with chemotherapy combined with radiotherapy for 2 months, and subsequent MRI results showed that the recurrent tumor volume was significantly reduced. As a result, radiotherapy was stopped. The patient remains alive, and his general condition has clearly improved.
 ...
PMID:Primary Urothelial Carcinoma of the Prostate with Glandular Differentiation: A Case Report. 2513 97